Showing 7381-7390 of 9079 results for "".
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- US FDA Nod for Generic Protopichttps://practicaldermatology.com/news/us-fda-nod-for-generic-protopic/2461939/The United States Food & Drug Administration (FDA) has approved Tacrolimus Ointment, 0.03%, Glenmark Pharmaceuticals’ generic version of Protopic Ointment, 0.03%. Glenmark's Tacrolimus Ointment, 0.03%, will be distributed in the U.S. by Glenmark Pharma
- Wristbands May Be Home to E. coli, Staphhttps://practicaldermatology.com/news/wristbands-may-be-home-to-e-coli-staphylococcus/2461937/Common wristbands can be ‘hotbed’ for harmful bacteria including E. coli, staphylococcus, according to new research. Researchers from Florida Atlantic University’s Charles E. Schmidt Colleg
- Leprosy Cases Rise in Florida: What Do Dermatologists Need to Know?https://practicaldermatology.com/news/leprosy-cases-rise-in-florida-what-do-dermatologists-need-to-know/2461935/Leprosy is making headlines because of an outbreak in Florida, and although this disease is still rare, it should be on dermatologists' radar, says Carrie Kovarik, MD, a professor of dermatology and medicine at Perelman School of Medicine at the University of Pennsylvania in Philadelphia
- New Report Highlights Challenges in Evaluating Biosimilarshttps://practicaldermatology.com/news/new-report-highlights-challenges-in-evaluating-biosimilars/2461933/New research provides an overview of gaps and challenges in the value assessment of biosimilars and identifies potential approaches to address them. The report, “
- Research Uncovers Genes Dictating the Direction of Hair Whorlshttps://practicaldermatology.com/news/research-uncovers-genes-dictating-the-direction-of-hair-whorls/2461932/The first gene mapping study on human scalp hair whorls shows that hair whorl direction has a genetic basis and is affected by multiple genes, according to a new study in the Journal of Investigative Dermatology. A hair whorl is a pa
- MRF to Host the 2023 Philadelphia Miles for Melanoma 5Khttps://practicaldermatology.com/news/mrf-to-host-the-2023-philadelphia-miles-for-melanoma-5k/2461928/The Melanoma Research Foundation’s (MRF) nextl Miles for Melanoma nationwide 5K program will take place in Philadelphia event on Saturday, August 26, 2023, at the Philadelphia Zoo at 7:30am ET. Register to attend the Philadelphia Miles for Melanoma 5K event
- Found: 135 New Melanin Genes Responsible for Pigmentationhttps://practicaldermatology.com/news/found-135-new-melanin-genes-responsible-for-pigmentation/2461927/Researchers have discovered 135 new genes associated with pigmentation. “To understand what actually causes different amounts of melanin to be produced, we used a technology called CRISPR-Cas9 to genetically engineer cells,” explains study author
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic